Inhalopédia | Inhalers

Class
- Inhaled corticosteroid (ICS)
  Long-acting beta-2 agonist (LABA)
Active ingredient
- Fluticasone propionate
- Salmeterol (as the xinafoate salt)
Device
- Inhub®
Inhalers techniques and maintenance
Age
- 4 +
Typical use
- Asthma
  uncontrolled on low dose ICS
Asthma management principles
- COPD
  in addition to a LAMA, when exacerbating on dual bronchodilation (LAMA/LABA)
COPD management principles
Marketed strength
- 100/50 mcg
- 250/50 mcg
- 500/50 mcg
Number of doses
- 60 doses
Dose indicator
- Yes | Numerical
Usual adult dosage
- Low | 100/50 mcg – 1 inh BID
  Medium | 250/50 mcg – 1 inh BID
  High | 500/50 mcg – 1 inh BID
ICS dosing
Usual pediatric dosage
- 4-5 years
  
  Not recommended
  
  6-11 years
  Low | 100/50 mcg – 1 inh QD
  Medium | 250/50 mcg – 1 inh QD
  
  12-17 years
  See adult dosage
ICS dosing
Required inspiratory flow
- > 30 - 60 L/min
  Medium internal resistance (R3)
Inspiratory flows
Public coverage
- MN | Open/Regular Benefit
  All provinces except MN | Restricted Benefit with criteria
Provincial coverage criteria
Advantages
- Low cost
Disadvantages
- BID dosing
Side effects

Product monograph

Download

Wixela®